Navigation Links
Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program
Date:9/4/2008

pligen established a development program for Friedreich's ataxia. Over the past year, the Company has made significant progress in advancing this program, resulting in the identification of advanced lead compounds with improved potency and specificity. These lead compounds are currently being assessed in pharmacology and toxicology in order to determine if one is suitable for clinical development in Friedreich's ataxia. Repligen is also evaluating this family of compounds for activity in preclinical models of other neurodegenerative diseases including Huntington's disease and spinal muscular atrophy. The MDA grant will partially support the characterization of the lead compounds, including the evaluation of compounds in preclinical models of disease and the completion of the pharmacology and toxicology. The FARA and NAF grant will support the development of new methods to quantitate the impact of drug treatment on frataxin gene expression and frataxin protein in preclinical models and in patients. In further support of this development program, Repligen previously announced receipt of a grant from Go FAR (Friedreich's Ataxia Research), an Italian-based fundraising organization dedicated to raising donations for Friedreich's ataxia research, to develop a biomarker, which may be useful in monitoring the biochemical activity and guiding the dosing of a clinical candidate in patients.

Symptoms of Friedreich's ataxia typically emerge between the ages of 5 and 15 and often progress to severe disability, incapacitation or loss of life in early adulthood. Friedreich's ataxia is caused by a single gene defect that results in inadequate production of the protein frataxin. The protein frataxin appears to be essential for the proper functioning of the mitochondria, the power plant of both neural and muscle cells. Low levels of frataxin lead to degeneration of both the nerves controlling muscle movements in the arms and legs and the nerve tissue in the spinal cord. Approx
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 This research report “Biodegradable ... Based Plastics, Regenerated Cellulose, PCL), by Application (Packaging, ... Forecasts to 2019”, defines and segments the global ... of its global volume and value. , Browse ... through 178 Slides and in-depth TOC on “Biodegradable ...
(Date:10/25/2014)... Durham, NC (PRWEB) October 24, 2014 ... appears to overcome several pitfalls of current skin grafting ... scarring and produces hair. The method, outlined in the ... a breakthrough for treating deep skin injuries that result ... skin injury completely destroys the skin’s regenerative elements. These ...
(Date:10/25/2014)... YORK , Oct. 24, 2014 ... Inc. (ACCP), a biopharmaceutical company advancing patient care ... 1-for-50 reverse split of its common stock effective ... 24, 2014. PlasmaTech,s common stock will trade on ... and temporary ticker symbol "ACCPD". After 20 days, ...
(Date:10/25/2014)... 24, 2014 Research and Markets ... by Product , Research Area & by End User ... offering. In this report, the global ... research areas, and end users. The product segments of ... instruments & consumables, kits, and reagents. The subsegments of ...
Breaking Biology Technology:Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 2New engineering method shows promise for faster healing, more cosmetically appealing skin grafts 3PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3
... Guide, ,I. Description ,II. Product Components ... ,IV. Protocol for Extraction of DNA from Whole Blood ... Whole Blood ,VI. Quantification of Amplified Products ... Application Data , References , Contact Information ...
... ,I. Description ,II. Product Components ,III. ... Protocol for Extraction of DNA from Blood Card ... Card ,VI. Quantification of Amplified Products ,VII. ... , References , Contact Information , , ,Application ...
... , , ... , , , Mutations ... of the colon, pancreas, liver, spleen, stomach or lungs. The,CDKN2A/P16 gene is ... which point mutation is present,in patient tissue samples. Freshly frozen tumor sections ...
Cached Biology Technology:Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 2Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 3Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 4Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 5Protocol for GenomePlex Whole Genome Amplification ,from Whole Blood 6Protocol for GenomePlex Whole Genome Amplification from Blood Card 2Protocol for GenomePlex Whole Genome Amplification from Blood Card 3Protocol for GenomePlex Whole Genome Amplification from Blood Card 4Protocol for GenomePlex Whole Genome Amplification from Blood Card 5Protocol for GenomePlex Whole Genome Amplification from Blood Card 6Mutation detection for the,K- rasand P16 genes 2Mutation detection for the,K- rasand P16 genes 3Mutation detection for the,K- rasand P16 genes 4Mutation detection for the,K- rasand P16 genes 5Mutation detection for the,K- rasand P16 genes 6
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... Oregon and Washington land managers have a new synthesis ... eastside moist mixed-conifer (MMC) forests in the two states. ... Forests in Eastern Oregon and Washington: A Synthesis of ... Management, a general technical report published by the U.S. ... response to a request from managers for a synthesis ...
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... A tiny wasp that lays its eggs under the ... most diverse groups of insects on Earth. Now researchers ... thought. (To see an audio slide show on ... By combining ecological and genetic data with the painstaking ...
... risk during cardiac procedures. Doctors performing heart surgery also ... IAEA is helping to raise awareness of threats, through ... X-ray imaging systems. The issue of radiation protection ... of lengthy angioplasty and other cardiac interventions performed under ...
... insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts ... treatment, said researchers at Baylor College of Medicine in a ... Journal of Clinical Oncology. The finding gives impetus to ... various tumors. "These findings come at a critical time," ...
Cached Biology News:Diversity among parasitic wasps is even greater than suspected 2Diversity among parasitic wasps is even greater than suspected 3Protecting those who heal 2Growth factor predicts poor outcome in breast cancer 2
6B9...
... DNA polymerase from Thermus aquaticus expressed in ... 1 tube of 250 units enzyme/tube and ... DNA), is the same enzyme as AmpliTaq ... a proprietary separation process to ensure that ...
... • Enzyme concentration - 5 units/µL ,• ... higher yields ,• Leaves an 'A' ... DNA polymerase which exhibits very high activity ... applications. To ensure the quality of the ...
... AmpliTaq DNA Polymerase is the most thoroughly ... a testimony to its overall utility and ... it ideal for PCR applications. , ... results. ,, AmpliTaq DNA Polymerase is ...
Biology Products: